Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05101122 · ClinicalTrials.gov registry record · Phase 1
Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)
A Phase 1 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05101122: Completed Phase 1 study, sponsored by Apnimed.
NCT05101122 is a Phase 1 study that has completed, run by Apnimed. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05101122, a Phase 1 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The SEED study is designed to assess the safety and efficacy for Obstructive Sleep Apnea (OSA) of 3 escalating dose combinations of atomoxetine with AD313 compared to baseline and to atomoxetine alone.
Primary Outcome
Compares high dose atomoxetine (80/10) versus baseline
Interventions
- DRUG Dosing 1: Atomoxetine
- DRUG AD313
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
What the finished NCT05101122 record still lists
NCT05101122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Dosing 1: Atomoxetine is the first listed.
NCT05101122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05101122 about?
NCT05101122 is a clinical study titled "Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)". The SEED study is designed to assess the safety and efficacy for Obstructive Sleep Apnea (OSA) of 3 escalating dose combinations of atomoxetine with AD313 compared to baseline and to atomoxetine alone.
What is the current status of trial NCT05101122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-10-19. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT05101122?
The interventions under investigation include: Dosing 1: Atomoxetine (DRUG), AD313 (DRUG).
Who is sponsoring clinical trial NCT05101122?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05101122's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI